1335501-35-3Relevant academic research and scientific papers
An orally available BACE1 inhibitor that affords robust CNS Aβ reduction without cardiovascular liabilities
Cheng, Yuan,Brown, James,Judd, Ted C.,Lopez, Patricia,Qian, Wenyuan,Powers, Timothy S.,Chen, Jian Jeffrey,Bartberger, Michael D.,Chen, Kui,Dunn, Robert T.,Epstein, Oleg,Fremeau, Robert T.,Harried, Scott,Hickman, Dean,Hitchcock, Stephen A.,Luo, Yi,Minatti, Ana Elena,Patel, Vinod F.,Vargas, Hugo M.,Wahl, Robert C.,Weiss, Matthew M.,Wen, Paul H.,White, Ryan D.,Whittington, Douglas A.,Zheng, Xiao Mei,Wood, Stephen
, p. 210 - 215 (2015)
BACE1 inhibition to prevent Aβ peptide formation is considered to be a potential route to a disease-modifying treatment for Alzheimer's disease. Previous efforts in our laboratory using a combined structure- and property-based approach have resulted in th
SPIRO-TETRACYCLIC RING COMPOUNDS AS BETA - SECRETASE MODULATORS
-
Page/Page column 329, (2011/10/10)
The present invention comprises a new class of compounds useful for the modulation of Beta-secretase enzyme activity and for the treatment of Beta-secretase mediated diseases, including Alzheimer's disease (AD) and other related conditions. In one embodiment, the compounds have a general Formula (I) wherein A1, A2, A3, A4, A5, A6, R2, R7, X and Y of Formula I are defined herein. The invention also includes use of these compounds in pharmaceutical compositions for treatment, prophylactic or therapeutic, of disorders and conditions related to the activity of beta-secretase protein. Such disorders include, for example, Alzheimer's Disease, cognitive deficits, cognitive impairment, schizophrenia and other central nervous system conditions related to and/or caused by the formation and/or deposition of plaque on the brain. The invention also comprises further embodiments of Formula I, intermediates and processes useful for the preparation of compounds of Formula I.
